**Core Concept**
The question is testing the student's knowledge of the pharmacological properties of antidiabetic medications, specifically their potential to cause hypoglycemia. The correct answer is a medication that is known to have a high risk of causing hypoglycemia when used as monotherapy in the treatment of type 2 diabetes.

**Why the Correct Answer is Right**
Metformin is the correct answer because it works by decreasing hepatic glucose production and increasing insulin sensitivity. However, it does not cause a significant increase in insulin secretion, which is why it is less likely to cause hypoglycemia. When used as a monotherapy, metformin is generally not associated with hypoglycemia, making it a safer option for patients with type 2 diabetes. In contrast, other antidiabetic medications like sulfonylureas and meglitinides stimulate insulin secretion, which can lead to hypoglycemia.

**Why Each Wrong Option is Incorrect**
**Option A:** Sulfonylureas, such as glipizide, cause hypoglycemia by stimulating insulin secretion from the beta cells of the pancreas. This makes them a high-risk option for causing hypoglycemia when used as monotherapy.
**Option B:** Meglitinides, such as repaglinide, also stimulate insulin secretion and are known to cause hypoglycemia, especially when used in combination with other antidiabetic medications.
**Option C:** Pioglitazone is a thiazolidinedione that increases insulin sensitivity, but it is not typically associated with hypoglycemia when used as monotherapy.

**Clinical Pearl / High-Yield Fact**
It's essential to remember that the risk of hypoglycemia is higher when using medications that stimulate insulin secretion, such as sulfonylureas and meglitinides, especially in patients with type 2 diabetes. Always assess the patient's risk factors for hypoglycemia and monitor their blood glucose levels closely when initiating or adjusting therapy.

**Correct Answer:** D. Pioglitazone